posted on 2009-05-14, 00:00authored byJohn A. Christopher, Paul Bamborough, Catherine Alder, Amanda Campbell, Geoffrey J. Cutler, Kenneth Down, Ahmed M. Hamadi, Adrian M. Jolly, Jeffrey K. Kerns, Fiona S. Lucas, Geoffrey W. Mellor, David D. Miller, Mary A. Morse, Kiritkant D. Pancholi, William Rumsey, Yemisi E. Solanke, Rick Williamson
The identification and progression of a potent and selective series of isoquinoline inhibitors of IκB kinase-β (IKK-β) are described. Hit-generation chemistry based on IKK-β active-site knowledge yielded a weakly potent but tractable chemotype that was rapidly progressed into a series with robust enzyme and cellular activity and significant selectivity over IKK-α.